-
2
-
-
42549162084
-
Eliminating human tuberculosis in the twenty-first century
-
DOI 10.1098/rsif.2007.1138, PII N502JJ12W45R6403
-
Dye C, Williams B G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 2008; 5: 653-662. (Pubitemid 351589747)
-
(2008)
Journal of the Royal Society Interface
, vol.5
, Issue.23
, pp. 653-662
-
-
Dye, C.1
Williams, B.G.2
-
3
-
-
33645673162
-
Targets for global tuberculosis control
-
Dye C, Maher D, Weil D, Espinal M, Raviglione M. Targets for global tuberculosis control. Int J Tuberc Lung Dis 2006; 10: 460-462.
-
(2006)
Int J Tuberc Lung Dis
, vol.10
, pp. 460-462
-
-
Dye, C.1
Maher, D.2
Weil, D.3
Espinal, M.4
Raviglione, M.5
-
5
-
-
0014095263
-
A controlled trial of community-wide isoniazid prophylaxis in Alaska
-
Comstock G W, Ferebee S H, Hammes L M. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95: 935-943.
-
(1967)
Am Rev Respir Dis
, vol.95
, pp. 935-943
-
-
Comstock, G.W.1
Ferebee, S.H.2
Hammes, L.M.3
-
6
-
-
0015428195
-
Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population
-
Comstock G W, Woolpert S F. Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population. Arch Environ Health 1972; 25: 333-337.
-
(1972)
Arch Environ Health
, vol.25
, pp. 333-337
-
-
Comstock, G.W.1
Woolpert, S.F.2
-
7
-
-
0018760256
-
Isoniazid prophylaxis among Alaskan Eskimos: A final report of the Bethel isoniazid studies
-
Comstock G W, Baum C, Snider D E, Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979; 119: 827-830.
-
(1979)
Am Rev Respir Dis
, vol.119
, pp. 827-830
-
-
Comstock, G.W.1
Baum, C.2
Snider Jr., D.E.3
-
8
-
-
0014635275
-
Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area
-
Horwitz O, Wilbek E, Erickson P A. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ 1969; 41: 95-113.
-
(1969)
Bull World Health Organ
, vol.41
, pp. 95-113
-
-
Horwitz, O.1
Wilbek, E.2
Erickson, P.A.3
-
9
-
-
18844479969
-
Population screening and mass chemoprophylaxis in Kiribati
-
Daulako E C. Population screening and mass chemoprophylaxis in Kiribati. Int J Lepr Other Mycobact Dis 1999; 67 (Suppl): S23-S25.
-
(1999)
Int J Lepr Other Mycobact Dis
, vol.67
, Issue.SUPPL.
-
-
Daulako, E.C.1
-
10
-
-
83155182847
-
Three months of rifapentine and isoniazid for latent tuberculosis infection
-
Sterling T R, Villarino ME, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
-
(2011)
N Engl J Med
, vol.365
, pp. 2155-2166
-
-
Sterling, T.R.1
Villarino, M.E.2
Borisov, A.S.3
-
11
-
-
84921430332
-
Regimens of less than six months for treating tuberculosis
-
Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev 2000; (2): CD001362.
-
(2000)
Cochrane Database Syst Rev
, Issue.2
-
-
Gelband, H.1
-
12
-
-
84863584732
-
New drugs for the treatment of tuberculosis: Hope and reality
-
Grosset J H, Singer T G, Bishai W R. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16: 1005-1014.
-
(2012)
Int J Tuberc Lung Dis
, vol.16
, pp. 1005-1014
-
-
Grosset, J.H.1
Singer, T.G.2
Bishai, W.R.3
-
13
-
-
34548678627
-
Asymptomatic hepatotoxicity in patients treated for tuberculosis and latent tuberculosis
-
DOI 10.1097/IPC.0b013e3181373d3a, PII 0001904820070900000006
-
Schlossberg D, Pritchett N, Nnumolu C. Asymptomatic hepatotoxicity in patients treated for tuberculosis and latent tuberculosis. Infect Dis Clin Pract 2007; 15: 320-323. (Pubitemid 47415196)
-
(2007)
Infectious Diseases in Clinical Practice
, vol.15
, Issue.5
, pp. 320-323
-
-
Schlossberg, D.1
Pritchett, E.N.2
Nnumolu, C.3
-
14
-
-
33749856322
-
An official ATS statement: Hepatotoxicity of antituberculosis therapy
-
DOI 10.1164/rccm.200510-1666ST
-
Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
-
(2006)
American Journal of Respiratory and Critical Care Medicine
, vol.174
, Issue.8
, pp. 935-952
-
-
Saukkonen, J.J.1
Cohn, D.L.2
Jasmer, R.M.3
Schenker, S.4
Jereb, J.A.5
Nolan, C.M.6
Peloquin, C.A.7
Gordin, F.M.8
Nunes, D.9
Strader, D.B.10
Bernardo, J.11
Venkataramanan, R.12
Sterling, T.R.13
-
15
-
-
0029781041
-
Liver injury during antituberculosis treatment: An 11-year study
-
DOI 10.1016/S0962-8479(96)90098-2
-
Dossing M, Wilcke J T, Askgaard D S, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tubercle Lung Dis 1996; 77: 335-340. (Pubitemid 26258538)
-
(1996)
Tubercle and Lung Disease
, vol.77
, Issue.4
, pp. 335-340
-
-
Dossing, M.1
Wilcke, J.T.R.2
Askgaard, D.S.3
Nybo, B.4
-
16
-
-
39449127844
-
-
Nuffield Council on Bioethics London, UK: Nuffield Council on Bioethics Accessed May 2014
-
Nuffield Council on Bioethics. Public health: ethical issues. London, UK: Nuffield Council on Bioethics, 2007. http://www.nuffieldbioethics.org/public- health. Accessed May 2014.
-
(2007)
Public Health: Ethical Issues
-
-
-
17
-
-
18944366612
-
Prevention of leprosy using rifampicin as chemoprophylaxis
-
Bakker M I, Hatta M, Kwenang A, et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg 2005; 72: 443-448. (Pubitemid 41278855)
-
(2005)
American Journal of Tropical Medicine and Hygiene
, vol.72
, Issue.4
, pp. 443-448
-
-
Bakker, M.I.1
Hatta, M.2
Kwenang, A.3
Van Benthem, B.H.B.4
Van Beers, S.M.5
Klatser, P.R.6
Oskam, L.7
|